SCHEMBL2376919

SCHEMBL2376919

C[Si](C)(C)CCOCn1ccc2nc(NC(=O)NC3CC4CCC3C4)cnc21

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 5/20 0.40
PDGFRB P09619 3/20 0.36
PDGFRA P16234 3/20 0.36
ALDH1A1 P00352 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
JAK2 O60674 3/20 0.34
JAK3 P52333 2/20 0.34
HPGD P15428 2/20 0.34
MAPT P10636 1/20 0.34
KDM4E B2RXH2 1/20 0.34
TSHR P16473 1/20 0.34
HSD17B10 Q99714 1/20 0.34
DGAT1 O75907 1/20 0.34
LMNA P02545 1/20 0.33
IDH1 O75874 1/20 0.33
JAK1 P23458 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2375791 0.88 TAS1R3 (0.41) ALDH1A1MEN1KMT2AJAK2JAK3
SCHEMBL2375797 0.88 TAS1R3 (0.41) ALDH1A1MEN1KMT2AJAK2JAK3
SCHEMBL2375794 0.88 TAS1R3 (0.41) ALDH1A1MEN1KMT2AJAK2JAK3
SCHEMBL2378417 0.87 TAS1R3 (0.40) ALDH1A1MEN1KMT2AJAK2JAK3
SCHEMBL2377659 0.85 JAK2 (0.48) ALDH1A1SMN1; SMN2MEN1KMT2AJAK2
SCHEMBL2376895 0.85 JAK2 (0.35) JAK2JAK3DGAT1JAK1
SCHEMBL2378461 0.84 CYP11B2 (0.34) JAK2JAK3DGAT1JAK1
SCHEMBL2377203 0.84 JAK2 (0.35) JAK2JAK3DGAT1JAK1
SCHEMBL2502761 0.84 JAK2 (0.36) JAK2JAK3MAPTDGAT1JAK1
SCHEMBL2502754 0.84 JAK2 (0.36) JAK2JAK3MAPTDGAT1JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2373653-A1 PYRROLOPYRAZINYL UREA KINASE INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-10-12 EP disclosed
US-8012974-B2 Pyrrolopyrazinyl urea kinase inhibitors ROCHE PALO ALTO LLC (US) 2011-09-06 US disclosed
WO-2010063634-A1 PYRROLOPYRAZINYL UREA KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-06-10 WO disclosed
US-20100144745-A1 Pyrrolopyrazinyl Urea Kinase Inhibitors ROCHE PALO ALTO LLC 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144745-A1 Pyrrolopyrazinyl Urea Kinase Inhibitors JAK1, JAK3, ULK3 EPHX2 3904/4885PDGFRB 2177/4885PDGFRA 2464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.